Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Limited has announced its guidance for the half year ending 30 June 2026, projecting sales between $46.3 million and $47.3 million, compared to $45.5 million in the same period of the previous year. Pre-tax profit is expected to be between $6.8 million and $7.3 million, in line with or slightly higher than the previous year's $6.8 million. The company anticipates significant revenue growth in its established markets of Australia and Malaysia/Singapore, which will be partially offset by reduced exports to China due to regulatory changes and channel dynamics. Despite challenging economic conditions, the company remains optimistic due to stringent cost control and high-quality earnings. Vita Life Sciences maintains a robust financial position with substantial cash reserves, no borrowings, and continuous cash generation to support strategic investments, while staying committed to its long-term growth strategy and shareholder value.